Table 2. Knowledge at baseline (T0, n = 50 patients), 1 month (T1, n = 50 patients) and 6 months (T6, n = 40 patients).
| Patients with 1 month evaluation (n = 50) | Patients with 1 and 6 month evaluation (n = 40) | ||||||
|---|---|---|---|---|---|---|---|
| Topic Number and percentage of patients with correct answers Mean degree of certainty (DC) | T0 | T1 | p-value T0/T1 | T0 | T1 | T6 | p value T0/T6 |
| blood cells | |||||||
| n, % | 36 (72%) | 45 (90%) | = 0.01 | 29 (72%) | 39 (97%) | 37 (92%) | >0.05 |
| Mean DC | 56 | 78 | <0.01 | 56 | 88 | 75 | <0.05 |
| Significance of « leukocytes » | |||||||
| n, % | 14 (28%) | 31 (62%) | <0.001 | 13 (32%) | 25 (62%) | 18 (45%) | >0.05 |
| Mean DC | 24 | 57 | <0.001 | 28 | 86 | 42 | = 0.01 |
| role of neutrophils | |||||||
| n, % | 13 (26%) | 21 (42%) | >0.05 | 9 (22%) | 17 (42%) | 13 (32%) | >0.05 |
| Mean DC | 22 | 38 | <0.05 | 19 | 87 | 32 | <0.05 |
| role of blood count | |||||||
| n, % | 15 (30%) | 25 (50%) | <0.05 | 12 (30%) | 21 (52%) | 14 (35%) | >0.05 |
| Mean DC | 28 | 48 | <0.05 | 28 | 91 | 32 | >0.05 |
| anti-thrombotic treatment | |||||||
| n, % | 42 (84%) | 48 (96%) | >0.05 | 38 (95%) | 39 (98%) | 33 (83%) | >0.05 |
| Mean DC | 83 | 90 | >0.05 | 83 | 92 | 87 | >0.05 |
| clinical signs of neutropenia | |||||||
| n, % | 21 (42%) | 42 (84%) | <0.001 | 16 (40%) | 34 (85%) | 28 (70%) | <0.05 |
| Mean DC | 41 | 74 | <0.001 | 40 | 89 | 56 | <0.05 |
| clinical signs of thrombopenia | |||||||
| n, % | 18 (36%) | 31 (62%) | <0.01 | 12 (30%) | 23 (57%) | 19 (47%) | >0.05 |
| Mean DC | 32 | 52 | <0.001 | 30 | 75 | 39 | >0.05 |
| clinical signs of formation of blood clots | |||||||
| n, % | 32 (64%) | 42 (84%) | <0.05 | 26 (65%) | 34 (85%) | 33 (82%) | >0.05 |
| Mean DC | 42 | 80 | <0.001 | 39 | 93 | 59 | <0.01 |
T0: baseline, T1: 1 month after educational session,T6: 6 months after educational session, DC: degree of certainty evaluated with a 6-point scale from 0 to 100%.